Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Single-center, Single-dose, Double-blind, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of TC-5214 in Healthy Recreational Polydrug Users

To see complete record on, please visit this link

Id: NCT01500018

Organisation Name: AstraZeneca

Overal Status: Withdrawn

Start Date: January 2012

Last Update: March 22, 2012

Lead Sponsor: AstraZeneca

Brief Summary: This is a single dose, crossover study to assess the abuse potential of TC-5214 compared to placebo, ketamine, and phentermine in healthy recreational polydrug users.

  • Drug Abuse
  • Healthy

Total execution time in seconds: 0.19387698173523